Novel Second-Generation Rexinoid Induces Growth Arrest and Reduces Cancer Cell Stemness in Human Neuroblastoma Patient-Derived Xenografts

Second-generation rexinoid 6-Methyl-UAB30 demonstrates superior anti-tumor effects in neuroblastoma patient-derived xenografts by reducing cancer stem cell populations and inducing differentiation. The compound decreased proliferation, CD133 expression, and stemness markers while showing a more favorable toxicity profile than current retinoic acid therapy, suggesting potential as novel maintenance treatment for high-risk neuroblastoma.